Visani G, Tosi P, Finelli C, Gamberi B, Zauli G, Cenacchi A, Fogli M, Colombini R, Tura S
Istituto di Ematologia L. e A. Seràgnoli, Università di Bologna, Italy.
Haematologica. 1992 Mar-Apr;77(2):142-5.
Recombinant (r) human (h) granulocyte/macrophage colony stimulating factor (rh GM-CSF) has been shown to increase the number of peripheral blood (PB) neutrophils, eosinophils and monocytes in myelodysplastic syndromes (MDS). The aims of this study were: 1) to evaluate the effect of rh GM-CSF therapy on the in vitro growth of granulocyte-erythroid-macrophage-megakaryocyte colonies (CFU-GEMM), erythroid colonies (BFU-E), and granulocyte-macrophage colonies (CFU-GM) in patients with MDS; 2) to assess in these patients, while they are being treated in vivo with rh GM-CSF, the possible additive effect of rh IL-3 and rh G-CSF on the in vitro growth of haematopoietic progenitors.
The in vitro growth of CFU-GEMM, BFU-E and CFU-GM was studies in 10 myelodysplastic (MDS) patients, before and after in vivo administration of rh GM-CSF.
After rh GM-CSF administration, the number of CFU-GM increased in all standard risk MDS patients. In 2 out of 5 cases, this effect was more pronounced and persisted up to 30 days after the end of rh GM-CSF treatment. On the other hand, the number of CFU-GEMM and BFU-E was substantially unchanged. When rh GM-CSF, rh G-CSF and rh IL-3 were added in vitro alone or in combination as the source of colony stimulating activity, no significant increase of the CFU-GM colony number was noticed.
Rh GM-CSF therapy appears useful for increasing the number of peripheral blood granulocytes and of marrow CFU-GM in standard-risk MDS patients. High-risk MDS patients are far less responsive to rh GM-CSF treatment, probably reflecting a more aggressive and/or advanced disease.
重组人粒细胞/巨噬细胞集落刺激因子（rh GM-CSF）已被证明可增加骨髓增生异常综合征（MDS）患者外周血中性粒细胞、嗜酸性粒细胞和单核细胞的数量。本研究的目的是：1）评估rh GM-CSF治疗对MDS患者体外粒细胞-红系-巨噬细胞-巨核细胞集落（CFU-GEMM）、红系集落（BFU-E）和粒细胞-巨噬细胞集落（CFU-GM）生长的影响；2）在这些患者接受rh GM-CSF体内治疗时，评估rh IL-3和rh G-CSF对造血祖细胞体外生长的可能相加作用。
对10例骨髓增生异常（MDS）患者在体内给予rh GM-CSF前后进行CFU-GEMM、BFU-E和CFU-GM的体外生长研究。
给予rh GM-CSF后，所有标准风险MDS患者的CFU-GM数量均增加。5例中有2例这种效应更明显，在rh GM-CSF治疗结束后持续长达30天。另一方面，CFU-GEMM和BFU-E的数量基本未变。当单独或联合添加rh GM-CSF、rh G-CSF和rh IL-3作为集落刺激活性来源时体外培养时，未观察到CFU-GM集落数量有显著增加。
Rh GM-CSF治疗似乎有助于增加标准风险MDS患者外周血粒细胞数量和骨髓CFU-GM数量。高危MDS患者对rh GM-CSF治疗的反应要小得多，这可能反映了疾病更具侵袭性和/或更晚期。
